BioNTech SE share price logo

BioNTech SE

NASDAQ: BNTX

Large Cap

$96.90

+0.05

(+0.05%)

as on

BioNTech SE Stock Performance

as on October 3, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $96.22
    $98.00
    downward going graph

    0.70%

    Downside

    1.14%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $79.52
    $124.00
    downward going graph

    17.94%

    Downside

    27.97%

    Upside

    downward going graph

BioNTech SE share price movements today

Previous Close
$96.85
Open
$97.01
Volume
562.0K
Market Cap
$24.7B
Day's Low - High
$96.22 - $98.00
52 Week Low - High
$79.52 - $124.00

BioNTech SE Historical Returns

1 Month Return
-5.81 %
3 Month Return
-0.66 %
1 Year Return
-8.14 %
3 Year Return
-11.37 %
5 Year Return
-61.97 %

BioNTech SE Stock Fundamentals & Key Indicators

Check BioNTech SE market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$24.7B

EPS (TTM)

-6.73

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.43%

PE Ratio (TTM)

-12.89

Industry PE ratio

8.52

PEG Ratio

0.13

EBITDA

-941.1M

Revenue (TTM)

2.6B

Profit Margin

68.95%

Return On Equity TTM

-9.16%

BioNTech SE vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BioNTech SE with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BioNTech SE image
BioNTech SE
StrongBuy$24.7B-61.97%-12.8968.95%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$44.1B609.62%-23.340.00%0.00%
Moderna image
Moderna
Neutral$75.4B-44.29%-24.08-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.5B180.98%30.1986.04%0.00%
Regeneron image
Regeneron
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for BioNTech SE Stock including INR - Dollar returns

The BioNTech SE stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

BioNTech SE investment value today

Current value as on today

₹99,704

Returns

-₹296

(-0.30%)

Returns from BioNTech SE Stock

-₹8,143 (-8.14%)

Dollar Impact

₹7,847 (+7.85%)

Analyst Recommendation on BioNTech SE Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33333333333334% of analysts recommend a 'BUY' rating for BioNTech SE. Average target price of $116.12

BioNTech SE Share Price Target

Get share price movements and forecasts by analysts on BioNTech SE.

What analysts predicted

16.55%UPSIDE

Target Price

$116.12

Current Price

$96.9

Analyzed by

12 Analysts

High

$140

Target

$116.12

Low

$105

BioNTech SE target price $116.12, a slight upside of 16.55% compared to current price of $96.9. According to 12 analysts rating.

Indian Investors' Interest in BioNTech SE Stock

Search interest for BioNTech SE Stock has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-47% versus previous 30 day period

BioNTech SE Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
187
128
1,244
1,190
182
260
1,518
898
120
105
Gross Profit
128
68
1,065
946
99
184
1,370
568
-75
8
Operating Income
-507
-966
10
148
-534
-501
-46
-230
-671
-948
EBITDA
-288
-752
211
464
-368
-348
149
-55
-450
-584
Interest Expense
4
7
5
-
6
3
0
6
4
7
Depreciation
38
49
44
165
42
51
124
163
123
266
Income Before Tax
-331
-805
158
301
-445
-402
24
-225
-577
-858
Income Tax Expense
-16
2
-39
41
-29
-16
53
76
-36
-37
Net Income
-315
-807
198
259
-415
-386
-28
-302
-540
-820
Net Profit Margin
68.50%
53.54%
85.63%
79.54%
54.16%
70.71%
90.24%
63.27%
-63.17%
8.14%

BioNTech SE Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
61
127
108
482
18,976
17,310
3,819
2,751
2,756
Gross Profit
52
113
91
423
16,065
14,315
3,219
2,209
2,140
Operating Income
-61
-53
-181
-82
15,283
12,642
690
-1,314
-623
EBITDA
-74
-23
-143
-105
15,002
13,096
1,377
-367
-627
Interest Expense
0
1
1
1
5
15
7
13
13
Depreciation
10
21
33
38
75
123
183
298
367
Income Before Tax
-85
-47
-179
-145
15,046
12,954
1,186
-677
-1,009
Income Tax Expense
0
0
0
-161
4,753
3,519
255
-12
81
Net Income
-85
-48
-179
15
10,292
9,434
930
-665
-1,091
Net Profit Margin
84.87%
89.27%
83.98%
87.70%
84.66%
82.70%
84.29%
80.32%
77.64%

BioNTech SE Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-341
-869
217
276
-437
-438
-33
-302
-540
-834
Operating Cash Flow
-344
1,759
-687
-501
-821
132
854
299
-427
10
Investing Cash Flow
-2,501
-248
-162
649
1,312
-26
-995
-2,626
2,694
-103
Financing Cash Flow
-8
-24
-8
-8
-14
-14
-14
-13
26
-110
Change in Cash
-3,189
1,426
-379
-633
893
1,053
-195
-2,421
2,117
-275

BioNTech SE Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Mar 2020
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-85
-47
-179
-145
15,046
12,954
1,186
-677
-1,091
Operating Cash Flow
-52
-58
-198
-13
889
13,577
5,371
207
438
Investing Cash Flow
-52
-67
-77
-144
-566
-35
-6,954
-2,081
-2,371
Financing Cash Flow
-1
365
383
894
94
-1,419
-778
-45
-50
Change in Cash
-131
239
107
691
482
12,182
-2,211
-1,901
-931

Global Institutional Holdings in BioNTech SE

Check out the Institutions with significant holdings in BioNTech SE.

Funds
Holdings
Theofanis Kolokotrones
1.50%
John A. Gunn
1.46%
Dodge & Cox Funds
1.21%
Fidelity Contrafund
0.99%
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
0.90%
See all

BioNTech SE News & Key Events

  • img

    Today's Timeline - 30 September

    Wed, 08:31 PM

    -

    BioNTech's oncology pipeline faces challenges, but diversified strategies may provide new revenue streams.

    Wed, 10:01 PM

    -

    BioNTech announces Dareon-Rosetta35 trial for advanced lung cancer, expanding beyond vaccines.

    Thu, 02:00 AM

    -

    BioNTech CEO sells 66,000 shares under a trading plan established earlier.

Insights on BioNTech SE

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 575.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 82.2% return, outperforming this stock by 94.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -28.70M → -820.79M (in $), with an average decrease of 361.2% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 1.51B → 105.6M (in $), with an average decrease of 46.5% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, BNTX stock has moved down by -0.7%

About BioNTech SE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
OrganisationBioNTech SE
HeadquartersAn der Goldgrube 12, Mainz, RP, 55131, DE
IndustryBiotechnology
CEOUgur Sahin

Key Management of BioNTech SE

Name

Title

Dr. Ozlem Tureci M.D.

Co-Founder, Chief Medical Officer & Member of Management Board

Mr. Ramon Zapata-Gomez

CFO & Member of Management Board

Dr. Sierk Pötting Ph.D.

MD, COO & Member of Management Board

Ms. Annemarie Hanekamp

Chief Commercial Officer & Member of Management Board

Ms. Kylie Jimenez

Chief People Officer & Member of Management Board

Ms. Lisa Birringer

Senior Vice President of Global Financial Reporting & Accounting

Mr. Douglas Maffei Ph.D.

Vice President of Strategy & Investor Relations

Dr. Ugur Sahin M.D.

Co-Founder, CEO & Chair of the Management Board

Jasmina Alatovic

Vice President Corporate Communications

Dr. James Timothy Patrick Ryan Ph.D.

Chief Legal & Business Officer and Member of the Management Board

FAQs

What is BioNTech SE share price today?

BioNTech SE share price today is $96.90 as on at the close of the market. BioNTech SE share today touched a day high of $98.00 and a low of $96.22.

What is the 52 week high and 52 week low for BioNTech SE share?

BioNTech SE share touched a 52 week high of $124.00 on and a 52 week low of $79.52 on . BioNTech SE stock price today i.e. is closed at $96.90,which is 21.85% down from its 52 week high and 21.86% up from its 52 week low.

What is BioNTech SE's market capitalisation today?

BioNTech SE market capitalisation is $0.02T as on .

How to invest in BioNTech SE Stock (BNTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for BioNTech SE on INDmoney app. Click on Buy button.

What is the minimum amount required to buy BioNTech SE Stock (BNTX) from India?

Indian investors can start investing in BioNTech SE (BNTX) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in BioNTech SE stock (as per the Rupee-Dollar exchange rate as on ). Based on BioNTech SE share’s latest price of $96.90 as on October 3, 2026 at 8:45 am IST, you will get 0.1032 shares of BioNTech SE. Learn more about fractional shares .

What are the returns that BioNTech SE has given to Indian investors in the last 5 years?

BioNTech SE stock has given -61.97% share price returns and 29.14% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?